Fresenius Medical Care AG (FMCQF)
| Market Cap | 13.16B -10.5% |
| Revenue (ttm) | 23.05B +2.1% |
| Net Income | 842.65M +9.0% |
| EPS | 2.86 +8.6% |
| Shares Out | n/a |
| PE Ratio | 15.61 |
| Forward PE | 10.96 |
| Dividend | 1.62 (3.61%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 160 |
| Average Volume | 4,542 |
| Open | 45.00 |
| Previous Close | 46.38 |
| Day's Range | 45.00 - 45.00 |
| 52-Week Range | 44.43 - 61.84 |
| Beta | 0.94 |
| RSI | 37.54 |
| Earnings Date | Feb 24, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial numbers in EUR Financial StatementsNews
Fresenius Medical Care: Low Confidence On Growth Acceleration Limits Upside
Fresenius Medical Care AG (FMS) Shares Down 3.69% on Jan 20
Fresenius Medical Care AG (FMS) Shares Down 3.69% on Jan 20
Fresenius Medical Care AG at JPMorgan Healthcare Conference Transcript
Fresenius Medical Care AG at JPMorgan Healthcare Conference Transcript
Fresenius Medical Care AG (FMS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fresenius Medical Care AG (FMS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 2:15 PM ESTCompany ParticipantsHelen Giza - Chair of...
Fresenius Medical Care AG (FMS) Stock Price Down 3.82% on Jan 13
Fresenius Medical Care AG (FMS) Stock Price Down 3.82% on Jan 13
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, signif...
DAX Up Marginally; Fresenius Medical Care Rises On Buy-back Announcement
(RTTNews) - German stocks gained marginal ground in positive territory Friday morning. Data showing an unexpected growth in the nation's industrial output in the month of November aided sentiment. Inv...
Fresenius Medical Care Continues EUR 1 Bln Share Buyback With Second Tranche
(RTTNews) - Fresenius Medical Care AG (FMS, FME.DE), on Friday announced the continuation of its share buyback programme with a second tranche, following the early completion of the first tranche on D...
Do Options Traders Know Something About FMS Stock We Don't?
Investors need to pay close attention to Fresenius Medical Care stock based on the movements in the options market lately.
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS's acquisitions, partnerships and global reach fuel growth, even as rising costs and optimization efforts weigh on near-term performance.
Fresenius Medical (FMS) Appoints New Chief Medical Officer for 2026
Fresenius Medical (FMS) Appoints New Chief Medical Officer for 2026
Fresenius Medical Names Charles Hugh-Jones Global CMO
(RTTNews) - Fresenius Medical Care AG (FMS, FME.DE), a provider of dialysis products and services, on Wednesday announced that it has appointed Charles Hugh-Jones as Global Chief Medical Officer on Ja...
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board
Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Ger...
Fresenius Medical Care: 'Buy' Again Following A Peak In May
Fresenius Medical Care (FMS) is rated a 'Buy,' citing strong fundamentals. FMS demonstrates robust revenue growth, margin expansion, and dividend safety, with a new HVHDF product rollout expected to d...
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives Propel Performance
Q3 2025 Fresenius Medical Care AG Earnings Call Transcript
Q3 2025 Fresenius Medical Care AG Earnings Call Transcript
Fresenius Medical Care is Now Oversold (FMS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Fresenius Medical Care (FMS) Shares Cross Below 200 DMA
In trading on Tuesday, shares of Fresenius Medical Care (Symbol: FMS) crossed below their 200 day moving average of $25.80, changing hands as low as $23.68 per share. Fresenius Medical Care shares are...
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at cons...
Fresenius Medical Care Q3 Results Climb, Maintains FY25 Outlook
(RTTNews) - Fresenius Medical Care AG (FMS, FME.DE) reported Tuesday higher profit and revenues in its third quarter, and maintained fiscal 2025 outlook.
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take ...
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation...
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hof...